Molecular Pathology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaillard, C
Right arrow Articles by Perbal, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaillard, C
Right arrow Articles by Perbal, B
Molecular Pathology 2002;55:325-335
© 2002 Journal of Clinical Pathology


ORIGINAL ARTICLE

Alteration of C-MYB DNA binding to cognate responsive elements in HL-60 variant cells

C Gaillard1, E Le Rouzic2, C Créminon2 and B Perbal1

1 Laboratoire d’Oncologie Virale et Moléculaire, U.F.R. de Biochimie, Université Paris 7 (D. Diderot), 75005 Paris, France
2 Service de Pharmacologie et d’immunologie DRM, CEA, 91190 Saclay, France

Correspondence to:
Professor B Perbal, Laboratoire d’Oncologie Virale et Moléculaire, UFR de Biochimie, Université Paris 7 - D. Diderot, 2 Place Jussieu, 75005 Paris, France;
perbal{at}ccr.jussieu.fr

Aims: To establish whether the MYB protein expressed in HL-60 variant cells, which are cells resistant to 12-O-tetradecanoylphorbol-13-acetate (TPA) induced differentiation, is able to bind MYB recognition elements (MREs) involved in the transcriptional regulation of myb target genes. In addition, to determine whether alterations in the binding of the MYB protein to MREs affects HL-60 cell proliferation and differentiation.

Methods: Nuclear extracts of HL-60 variant cells exhibiting different degrees of resistance to TPA induced monocytic differentiation were used in electrophoretic mobility shift experiments (EMSAs), bandshift experiments performed with labelled oliogonucleotides containing the MYB consensus binding sequences.

Results: The MYB protein contained in nuclear extracts from HL-60 variant cells did not bind efficiently to the MYB recognition elements identified in the mim-1 and PR264 promoters. Molecular cloning of the myb gene and analysis of the MYB protein expressed in the HL-60 variant cells established that the lack of binding did not result from a structural alteration of MYB in these cells. The lack of MRE binding did not abrogate the ability of variant HL-60s to proliferate and to undergo differentiation. Furthermore, the expression of the PR264/SC35 splicing factor was not affected as a result of the altered MYB DNA binding activity.

Conclusions: Because the MYB protein expressed in HL-60 variant cells did not appear to be structurally different from the MYB protein expressed in parental HL-60 cells, it is possible that the HL-60 variant cells contain a MYB binding inhibitory factor (MBIF) that interferes with MYB binding on MREs. The increased proliferation rate of HL-60 variant cells and their reduced serum requirement argues against the need for direct MYB binding in the regulation of cell growth.


Keywords: c-myb; MYB recognition elements; HL-60; TPA; monocytic differentiation; SC35; PR264

Abbreviations: EMSA, electrophoretic mobility shift experiment; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MBIF, MYB binding inhibitory factor; MRE, MYB recognition element; TPA, 12-O-tetradecanoylphorbol-13-acetate







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Molecular Pathology Journal of Clinical Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.